

# SECURITIES AND EXCHANGE COMMISSION

## FORM 6-K

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Filing Date: **2013-06-10** | Period of Report: **2013-06-10**  
SEC Accession No. [0001104659-13-048030](#)

([HTML Version](#) on [secdatabase.com](#))

### FILER

#### **GW PHARMACEUTICALS PLC**

CIK: **1351288** | IRS No.: **000000000**

Type: **6-K** | Act: **34** | File No.: **001-35892** | Film No.: **13903193**

SIC: **2834** Pharmaceutical preparations

#### Mailing Address

*PORTON DOWN SCINECE  
PARK  
SALISBURY WILSHIRE SP4  
OJQ UK X0 00000*

#### Business Address

*PORTON DOWN SCINECE  
PARK  
SALISBURY WILSHIRE SP4  
OJQ UK X0 00000  
44-1-9-80557-000*

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**Form 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June, 2013**

**Commission File Number: 001-35892**

---

**GW PHARMACEUTICALS PLC**

(Translation of registrant's name into English)

---

**Porton Down Science Park, Salisbury  
Wiltshire, SP4 0JQ  
United Kingdom**

(Address of principal executive offices)

---

(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)

Form 20-F       Form 40-F

(Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1))

Yes       No

(Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7))

Yes       No

---

---

---

## Notification of Interests of Directors and Connected Persons

On June 10, 2013, GW Pharmaceuticals plc (the "Company") issued a press release announcing that Chris Tovey, Chief Operations Officer of the Company, purchased 7,500 ordinary shares of the Company. The press release is attached as Exhibit 99.1 and is incorporated by reference herein.

### Exhibits

99.1 Press Release dated June 10, 2013

2

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **GW Pharmaceuticals plc**

By: /s/ Adam George

Name: Adam George

Title: Chief Financial Officer

Date: June 10, 2013

3

---

**GW Pharmaceuticals PLC Director/PDMR Shareholding**

GW Pharmaceuticals PLC (“GW Pharmaceuticals” or the “Company”)

NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS

Porton Down, UK, 10 June 2013: GW Pharmaceuticals (AIM: GWP) hereby provides notification that the Company has today been notified that Chris Tovey, Chief Operations Officer of the Company, has today purchased 7,500 0.1 pence ordinary shares of GW Pharmaceuticals plc at a purchase price of 48.25 pence per share.

Following this notification Mr Tovey’s total beneficial interest in the 0.1 pence ordinary shares of GW Pharmaceuticals plc has increased to 12,500 shares, representing less than 0.1% of the Company’s current issued share capital.

The total number of shares outstanding in the Company is 177,506,354 ordinary shares of 0.1 pence each.

Enquiries:

GW Pharmaceuticals PLC Tel: +44 (0)1980 557 000

Adam George, Company Secretary

Peel Hunt LLP (Nominated Adviser) Tel: +44 (0)207 418 8900

James Steel/Vijay Barathan

---